Unknown

Dataset Information

0

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer.

ABSTRACT: The management of advanced castration resistant prostate cancer (CRPC) has been rapidly changing and is still evolving. In the last years, there has been an increasing knowledge of prostate cancer biology. New therapeutic agents and approaches have been evaluated demonstrating benefits in survival and quality of life in patients with metastatic prostate cancer.

SUBMITTER: Recine F 

PROVIDER: S-EPMC4708230 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer.

Recine Federica F   Sternberg Cora N CN  

Translational andrology and urology 20150601 3

The management of advanced castration resistant prostate cancer (CRPC) has been rapidly changing and is still evolving. In the last years, there has been an increasing knowledge of prostate cancer biology. New therapeutic agents and approaches have been evaluated demonstrating benefits in survival and quality of life in patients with metastatic prostate cancer. ...[more]

Similar Datasets

Unknown Advances in hormonal therapies for hormone naive and castration-resistant prostate cancers with or without previous chemotherapy.
| S-EPMC4918127 | biostudies-literature
Unknown Chemotherapy options in castration-resistant prostate cancer.
| S-EPMC5054655 | biostudies-literature
Unknown Phase-1 study of abiraterone acetate in chemotherapy-naive Japanese patients with castration-resistant prostate cancer.
| S-EPMC4462344 | biostudies-literature
Unknown Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.
| S-EPMC3928129 | biostudies-literature
Unknown Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
| S-EPMC7738850 | biostudies-literature
Unknown Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naive metastatic castration-resistant prostate cancer in Japan.
| S-EPMC8326386 | biostudies-literature
Unknown Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
| S-EPMC8616757 | biostudies-literature
Unknown Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models.
| S-EPMC3230051 | biostudies-literature
Unknown Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
| S-EPMC5570461 | biostudies-literature
Unknown U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer.
| S-EPMC4524760 | biostudies-other